No significant increases in risk of any of the thyroid cancer subtypes were identified with GLP1 receptor agonist use, although the number of events was relatively small and the estimates for subtypes other than papillary were imprecise (table 2). Here, GLP1R is linked to thyroid gland carcinoma.